? DEVELOPMENTAL FUNDS The OSUCCC has provided seed funding for faculty recruitment and shared resource development. During the current grant cycle, 17 faculty were recruited, 8 of which were at the associate or full professor level. These faculty were strategically recruited to all 5 research programs and most focus on research relevant to the OSUCCC catchment area. They span 5 different colleges, 10 different departments across the colleges, and include Nationwide Children?s Hospital. Developmental funds used to support these faculty was $1,937,467. These investigators received $32,567,789 in NCI funding and $35,813,889 total peer-review funding, yielding a return on investment from CCSG developmental funds of 18:1. For the current funding cycle, we also established two developing shared resources (permitted under the prior CCSG guidelines), which were the Solid Tumor Translational developing Shared Resource (STTdSR) and the Veterinary Clinical Research Support Developing Shared Resource (VCRSdSR). The STTdSR has matured and is now called the Clinical-Translational Science Shared Resource (CTSSR) to reflect more broad use to include investigators focused on hematological malignancies and population science, in addition to those doing solid tumor research. Funding for this shared resource is requested in the current CCSG application. The VCRSdSR remains a developing shared resource; however, this will be supported from institutional funds and no CCSG funding is requested.
The Specific Aims for Developmental Funds are: 1) to expand innovative and high-impact science focused on our four strategic priorities: immuno-oncology, cancer engineering, translational genomics, and cancer prevention and survivorship; 2) to identify and recruit senior, midlevel and early career faculty whose scientific expertise targets relevant needs in the OSUCCC strategic plan and catchment area (CA); and, 3) to use a robust evaluation process and provide seed funding for research projects that are inter-programmatic collaborations and/or are community focused, leading to NCI funding at the R01- or P01-equivalent level. To achieve these aims, for the current application, funds are being requested for the recruitment of investigators (n=18) matched to the OSUCCC research priorities and programmatic and catchment area needs. The OSUCCC also is requesting funding to leverage our highly successful Pelotonia-funded pilot awards program, called the Intramural Research Program. This is an externally peer reviewed mechanism that prioritizes projects for funding based on scientific merit and research focused on our catchment area, with additional consideration for early stage investigators. CSSG pilot funding will specifically target synergistic projects spanning two or more research programs representing inter-programmatic collaborations, and/or or projects developing community partnerships (funding for new shared resources are requested in the Shared Resource Management budget). Developmental funds and the CCSG review process are a critical way that our university evaluates the impact of the OSUCCC and allows us to substantially leverage our ongoing and substantial institutional commitments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Pan, Pan; Huang, Yi-Wen; Oshima, Kiyoko et al. (2018) An immunological perspective for preventing cancer with berries. J Berry Res 8:163-175

Showing the most recent 10 out of 2602 publications